EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
The conference’s abstract drop features ASC4First in its plenary session.
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.